FILTER
FILTERED INTERVIEW RESULTS
Kendalle O’Connell
PRESIDENT AND COO, MASSBIO
MassBio explains how it intends to ensure that Massachusetts remains a global leader for life sciences.
Daphne Zohar & Bharatt Chowrira
FOUNDER AND CEO & PRESIDENT AND CHIEF OF BUSINESS AND STRATEGY, PURETECH HEALTH
PureTech Health is expanding swiftly with 24 product candidates that it has invented or initiated, 13 of which are in clinical testing, and two have received FDA clearance.
Peter DeYoung
CEO, PIRAMAL GLOBAL PHARMA
Piramal Global Pharma is responding to growing demand with rapid expansion in the CDMO space.
Gil Roth
PRESIDENT, PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION (PBOA)
PBOA explains why the CDMO sector enjoys a higher profile.
Debbie Hart
FOUNDING PRESIDENT & CEO, BIONJ
BioNJ relates how New Jersey’s thriving life sciences sector is benefitting from a tremendous boost.
Chris Garabedian
CHAIRMAN & CEO, XONTOGENY
Xontogeny explains how it can help young companies to cross the valley of death.
Rajiv Anand
FOUNDER AND CEO, QUARTIC.AI
Quartic AI explains how artificial intelligence and machine learning should be applied in life sciences.
Rajiv Anand
FOUNDER & CEO, QUARTIC AI
"Much of the focus of tech development has been for people in IT and data science. This creates a big barrier to adoption for chemists, biologists or chemical engineers, it is unsustainable. Overcoming those two barriers is the inspiration behind Quartic.ai."
Paul Hennessey
SENIOR VICE PRESIDENT – OPERATIONS, QUALITY AND TECHNICAL SERVICES, ADVANTICE HEALTH
Advantice Health provides consumer health care products and is focused on building a number of brands.
Dr. Jeffrey Reingold
COO, CONTRACT PHARMACAL CORP
CPC, a full-service contract manufacturer in the US, comments on the current business environment.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
